Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group trial 9346 (INT-0162)

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 3984-3990

  Hussain, Maha ^a   Tangen, Catherine M ^a   Higano, Celestia ^a   Schelhammer, Paul F ^a   Faulkner, James ^a   Crawford, E David ^a   Wilding, George ^a   Akdas, Atif ^a   Small, Eric J ^a   Donnelly, Bryan ^a   MacVicar, Gary ^a   Raghavan, Derek ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INTERMITTENT THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNIVARIATE ANALYSIS; BLOOD; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; PROSTATE TUMOR; RISK FACTOR; STATISTICAL MODEL; SURVIVAL; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748465540     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.4246     Document Type: Article

References (15)

1. Tangen CM, Faulkner JR, Crawford ED, et al: Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2:41-45, 2003
2. Eisenberger M, Crawford ED, McLeod D, et al: The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105. Proc Am Soc Clin Oncol 14:235, 1995 (abstr 613)
3. Goldenberg SL, Bruchovsky N, Gleave ME, et al: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 45:839-845, 1995
4. Oosterlinck W, Mattelaer J, Casselman J, et al: PSA evolution: A prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade - Data from a Belgian multicentric study of 546 patients. Acta Urol Belg 65:63-71, 1997
5. Collette L, Burzykowski T, Carroll KJ, et al: Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 23:6139-6148, 2005
6. Arai Y, Yoshiki T, Yoshida O: Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 144:1415-1419, 1990
7. Collette L, de Reijke TM, Schroder FH: Prostate specific antigen: A prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 44:182-189, 2003
8. Cooper EH, Armitage TG, Robinson MR, et al: Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 66: 1025-1028, 1990
9. Dijkman GA, Janknegt RA, De Reijke TM, et al: Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group. J Urol 158:160-163, 1997
10. Ercole CJ, Lange PH, Mathisen M, et al: Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 138:1181-1184, 1987
11. Fowler JE Jr, Pandey P, Seaver LE, et al: Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J Urol 153:1860-1865, 1995
12. Matzkin H, Soloway MS, Schellhammer PF, et al: Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen. Cancer 72:1286-1290, 1993
13. Miller JI, Ahmann FR, Drach GW, et al: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147:956-961, 1992
14. Reynard JM, Peters TJ, Gillatt D: Prostate-specific antigen and prognosis in patients with metastatic prostate cancer-A multivariable analysis of prostate cancer mortality. Br J Urol 75:507-515, 1995
15. Stamey TA, Kabalin JN, Ferrari M, et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate - IV, Antiandrogen treated patients. J Urol 141:1088-1090, 1989